Latest Press Releases
Nammi Therapeutics Featured in Los Angeles Business Journal
February 6, 2023
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and CEO of Nammi Therapeutic and highlighted the most recent achievements of the company including the CIRM award and Amgen Golden Ticket.
Amgen and BioLabs LA at The Lundquist Institute Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket
January 6, 2023
Biolabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California. Nammi Therapeutics will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.
This is the third Amgen Golden Ticket awarded to help accelerate life science startups in Southern California.
Nammi Therapeutics Awarded Grant by California Institute for Regenerative Medicine (CIRM)
December 15, 2022
The CIRM Board awarded $3,999,113 to Dr. David Stover and Nammi Therapeutics to complete the manufacture and testing needed to gain FDA permission for a clinical trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM, a “masked immunocytokine,” binds to and kills the tumor by activating the immune system.
Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of Pancreatic Cancer
June 16, 2022
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.
Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of Multiple Myeloma
June 13, 2022
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.